Understanding Your Birdshot Diagnosis
At a Glance
Birdshot chorioretinopathy is chronic inflammation of the choroid and retina in both eyes. It can affect night vision, glare, color, and peripheral vision even with 20/20 central vision, but specialist-guided treatment can suppress inflammation and protect remaining sight.
Receiving a diagnosis of Birdshot Chorioretinopathy (BSCR) often marks the end of a confusing period of “vague” visual symptoms and the beginning of a life-altering journey. It is completely normal to feel overwhelmed, anxious, or even relieved to finally have a name for what you are experiencing [1]. This condition is rare, and the path forward is a marathon rather than a sprint, but it is a manageable condition for many people with the right specialist care [2].
What is Birdshot?
Birdshot Chorioretinopathy is a chronic, bilateral (affecting both eyes) form of posterior uveitis—a type of inflammation that occurs in the back of the eye [3]. Specifically, it targets the choroid (the layer of blood vessels under the retina) and the retina itself [4].
The name “Birdshot” comes from the unique appearance of the eye during an exam: doctors often see small, light-colored spots scattered across the retina that resemble the pattern of birdshot pellets from a shotgun [4].
Understanding the Rarity and Demographics
Birdshot is considered a rare disease. While exact numbers are difficult to pin down, one specialized urban clinic found it accounted for only about 3% of their uveitis referrals [5].
- Who it affects: It most commonly appears in people of Northern European ancestry, typically in their 50s or 60s [6][7].
- Sex differences: Women are diagnosed more frequently than men, with some clinic cohorts showing a ratio of about 2.8 women for every 1 man [6].
- Exceptions: While these patterns exist, Birdshot can affect anyone. It has been documented in teenagers, people in their 80s, and across diverse racial and ethnic groups, including Hispanic and Chinese populations [8][9][10].
The Role of Genetics (HLA-A29)
Almost everyone with Birdshot carries a specific genetic marker called HLA-A29 [3].
- What it is: Think of HLA-A29 as a susceptibility marker that makes a person more likely to develop this specific type of inflammation [11].
- What it isn’t: Carrying the marker does not mean a person will definitely develop the disease, nor does it predict how severe the disease will be [11][12]. Many people in the general population have this marker and never develop any eye problems.
Moving Beyond “20/20” Vision
One of the most frustrating parts of a Birdshot diagnosis is that your “central vision” (the ability to read the 20/20 line on an eye chart) may remain perfect for a long time, even while you feel your vision is failing [13].
In reality, Birdshot often impacts functional vision first [14]. You may notice:
- Difficulty driving at night or in low light.
- Problems with glare or “shimmering” in your vision.
- A loss of color intensity or “washed out” colors [1].
- Blind spots (scotomas) or a narrowing of your peripheral (side) vision.
Because of this, your doctor will use more than just an eye chart to monitor you. They will use visual field tests to check your side vision and ERGs (electroretinograms) to measure how well your retina is responding electrically [15][16].
Outlook: A Chronic Condition
The most important thing to know today is that while outcomes vary, Birdshot is treatable. The goal of modern treatment is to suppress the inflammation to prevent further damage to the eye [16]. While existing damage may not reverse, appropriate treatment aims to protect the function you currently have.
While treatment often begins with corticosteroids (like prednisone) to bring active inflammation under control, the long-term strategy usually involves steroid-sparing immunomodulatory therapy [2]. These are medications that regulate the immune system without the long-term side effects of high-dose steroids.
In specialized research cohorts, a significant portion of patients—sometimes up to 75-80%—have been able to achieve inactive disease after years of consistent treatment [16][17]. However, this often requires staying on maintenance medications for a long time. You are not alone in this. Staying consistent with your specialist and your treatment plan is the most effective way to protect your sight [18].
Common questions in this guide
What does a Birdshot chorioretinopathy diagnosis mean?
If I have HLA-A29, does that confirm Birdshot chorioretinopathy?
How can Birdshot affect my vision if I still see 20/20?
Which tests are used to monitor Birdshot activity?
What treatments are used for Birdshot chorioretinopathy?
What is the long-term outlook with Birdshot chorioretinopathy?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Birdshot chorioretinopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my specific test results (OCT, visual fields, and ERG), what is the current activity level of my Birdshot?
- 2.What visual markers beyond '20/20' vision will we be using to track my progress and treatment success?
- 3.Am I a candidate for steroid-sparing therapy now, and what are the realistic long-term goals for my treatment?
- 4.How much experience does this clinic have in treating Birdshot chorioretinopathy specifically?
- 5.Are there local or online support groups or low-vision resources you recommend for patients with rare uveitis?
References
References (18)
- 1
Quality of Life in Patients with Birdshot Chorioretinitis Aged 80 and Older.
Kaisari E, Loeliger J, Thorne JE, et al.
Ocular immunology and inflammation 2025; (33(2)):280-286 doi:10.1080/09273948.2024.2400172.
PMID: 39250617 - 2
Birdshot Chorioretinopathy: A Review.
Bousquet E, Duraffour P, Debillon L, et al.
Journal of clinical medicine 2022; (11(16)) doi:10.3390/jcm11164772.
PMID: 36013011 - 3
Birdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment.
Minos E, Barry RJ, Southworth S, et al.
Orphanet journal of rare diseases 2016; (11(1)):61 doi:10.1186/s13023-016-0429-8.
PMID: 27175923 - 4
Birdshot retinochoroidopathy.
Vitale AT
Journal of ophthalmic & vision research 2014; (9(3)):350-61 doi:10.4103/2008-322X.143376.
PMID: 25667738 - 5
Epidemiology of uveitis in a Western urban multiethnic population. The challenge of globalization.
Llorenç V, Mesquida M, Sainz de la Maza M, et al.
Acta ophthalmologica 2015; (93(6)):561-7 doi:10.1111/aos.12675.
PMID: 25683136 - 6
Sex-Related Effects on the Clinical Presentation of Uveitis.
Samalia PD, Sims JL, Tomkins-Netzer O, et al.
American journal of ophthalmology 2026; (282()):82-89 doi:10.1016/j.ajo.2025.10.028.
PMID: 41642701 - 7
Choroidal Findings in Eyes With Birdshot Chorioretinitis Using Enhanced-Depth Optical Coherence Tomography.
Böni C, Thorne JE, Spaide RF, et al.
Investigative ophthalmology & visual science 2016; (57(9)):OCT591-9 doi:10.1167/iovs.15-18832.
PMID: 27599125 - 8
Birdshot chorioretinopathy presenting in a teenager.
Lee J, Smith WM, Goldstein DA
American journal of ophthalmology case reports 2020; (19()):100807 doi:10.1016/j.ajoc.2020.100807.
PMID: 32695925 - 9
Characteristics, Upon Presentation, of a Cohort of Hispanic Patients with Birdshot Retinochoroidopathy.
Marrero FM, De Jesus E, Alvarez S, et al.
Puerto Rico health sciences journal 2020; (39(3)):249-253.
PMID: 33031692 - 10
Birdshot chorioretinopathy in an HLA-A29 positive Asian patient.
Regenold J, Ghoraba H, Akhavanrezayat A, et al.
American journal of ophthalmology case reports 2023; (29()):101802 doi:10.1016/j.ajoc.2023.101802.
PMID: 36741421 - 11
Guidelines From the French-Speaking Society for Histocompatibility and Immunogenetics (SFHI) for Harmonisation of HLA Genotyping in Autoimmune Diseases, Drug Hypersensitivity and Pharmacogenetics.
Renac V, Moalic V, Dautin G, et al.
HLA 2025; (106(4)):e70442 doi:10.1111/tan.70442.
PMID: 41137743 - 12
The Impact of HLA-A29 Homozygosity and of the Second HLA-A Allele on Susceptibility and Severity of Birdshot Chorioretinitis.
Loeliger J, Lhotte R, Gelfman S, et al.
Investigative ophthalmology & visual science 2024; (65(13)):47 doi:10.1167/iovs.65.13.47.
PMID: 39570638 - 13
EVALUATION OF PHOTORECEPTORS, RETINAL CAPILLARY PLEXUSES, AND CHORIOCAPILLARIS IN PATIENTS WITH BIRDSHOT CHORIORETINOPATHY.
Forte R, Saleh M, Aptel F, Chiquet C
Retina (Philadelphia, Pa.) 2020; (40(5)):977-988 doi:10.1097/IAE.0000000000002457.
PMID: 30789462 - 14
Visual acuity and visual field as a function of disease duration in patients with birdshot chorioretinitis.
Loeliger J, Monnet D, Thorne J, et al.
The British journal of ophthalmology 2024; (108(11)):1543-1547 doi:10.1136/bjo-2023-324636.
PMID: 38508674 - 15
Short-Wavelength Automated Perimetry Parameters at Baseline and Following Remission in Patients With Birdshot Retinochoroidopathy.
Maleki A, Swan RT, Silpa-Archa S, et al.
American journal of ophthalmology 2016; (163()):83-92.e6 doi:10.1016/j.ajo.2015.11.024.
PMID: 26621683 - 16
Long-term outcomes of systemic corticosteroid-sparing immunomodulatory therapy for Birdshot Retinochoroidopathy.
You C, Lasave AF, Kubaisi B, et al.
Ocular immunology and inflammation 2020; (28(6)):966-974 doi:10.1080/09273948.2019.1641610.
PMID: 31567006 - 17
Treatment Outcomes in Birdshot Chorioretinitis: Corticosteroid Sparing, Corticosteroid Discontinuation, Remission, and Relapse.
Crowell EL, France R, Majmudar P, et al.
Ophthalmology. Retina 2022; (6(7)):620-627 doi:10.1016/j.oret.2022.03.003.
PMID: 35283323 - 18
Outcomes of "Early" Withdrawal of Corticosteroid Sparing Immunomodulatory Therapy for Birdshot Retinochoroidopathy.
You C, Meese H, Stephenson A, et al.
Ocular immunology and inflammation 2019; (27(7)):1165-1173 doi:10.1080/09273948.2018.1506040.
PMID: 30207810
This page explains Birdshot chorioretinopathy, its monitoring, and treatment for informational purposes only and does not constitute medical advice. Your uveitis or retina specialist should interpret your test results and guide your care.